AZD6244 (ARRY-142886) Solid Oral Dosage Formulation in Participants With Advanced Solid Malignancies
The primary purpose of the study is to assess the safety, tolerability and pharmacokinetics of a capsule of AZD6244 in participants with advanced solid malignancies.
Tumor|Cancer
DRUG: AZD6244
Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs) in Part A and Part B, An adverse event (AE) is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious adverse event (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. The TEAEs are defined as events present at baseline that worsened in intensity after administration of study drug or events absent at baseline that emerged after administration of study drug., Day 1 through 11.8 months (maximum observed duration)|Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs in Part A and Part B, Number of participants with abnormal clinical laboratory parameters reported as TEAEs are reported. Abnormal clinical laboratory parameters defined as any abnormal finding during analysis of hematology, clinical chemistry, and urinalysis., Day 1 through 11.8 months (maximum observed duration)|Number of Participants With Abnormal Vital Signs Reported as TEAEs in Part A and Part B, Number of participants with abnormal vital signs reported as TEAEs are reported. Abnormal vital signs are defined as any abnormal finding in the vital sign parameters (blood pressure, oxygen saturation, weight, and pulse rate)., Day 1 through 11.8 months (maximum observed duration)|Number of Participants With Abnormal Echocardiogram (ECHO) Parameters Reported as TEAEs in Part A and Part B, Number of participants with abnormal ECHO parameters reported as TEAEs are reported., Day 1 through 11.8 months (maximum observed duration)|Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs in Part A and Part B, Number of participants with abnormal ECG parameters reported as TEAEs are reported., Day 1 through 11.8 months (maximum observed duration)
Maximum Plasma Concentration (Cmax) of AZD6244 (Part A), The Cmax of AZD6244 in Part A is reported., Day 1: Pre-dose (within 30 minutes of dosing); 5, 15, and 30 minutes, 1, 1.5, 2, 4, 8, 12, and 24 hours post-dose; Day 8: Pre-dose (within 10 minutes of dosing); 5, 15, and 30 minutes, 1, 1.5, 2, 4, 8, and 12 hours post-dose|Cmax of AZD6244 (Part B Single Dose), The Cmax of AZD6244 in Part B is reported. Day 1 and Day 8 in Part B are the first days of two periods in crossover bioavailability assessment of two AZD6244 formulations: capsule versus the free-base suspension., Days 1 and 8: Pre-dose (within 30 minutes of dosing); 5, 15, and 30 minutes, 1, 1.5, 2, 4, 8, 12, and 24 hours post-dose|Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC) of AZD6244 (Part A), The AUC of AZD6244 in Part A is reported., Day 1: Pre-dose (within 30 minutes of dosing); 5, 15, and 30 minutes, 1, 1.5, 2, 4, 8, 12, and 24 hours post-dose|Area Under the Plasma Concentration-time Curve From Time Zero to 12 Hours Post Dose (AUC[0-12]) of AZD6244 (Part A), The AUC(0-12) of AZD6244 in Part A is reported., Day 8: Pre-dose (within 10 minutes of dosing); 5, 15, and 30 minutes, 1, 1.5, 2, 4, 8, and 12 hours post-dose|AUC of AZD6244 (Part B Single Dose), The AUC of AZD6244 in Part B is reported. Day 1 and Day 8 in Part B are the first days of two periods in crossover bioavailability assessment of two AZD6244 formulations: capsule versus the free-base suspension., Days 1 and 8: Pre-dose (within 30 minutes of dosing); 5, 15, and 30 minutes, 1, 1.5, 2, 4, 8, 12, and 24 hours post-dose|Area Under the Plasma Concentration-time Curve From Time Zero to 24 Hours Post Dose (AUC[0-24]) of AZD6244 (Part B Single Dose), The AUC(0-24) of AZD6244 in Part B is reported. Day 1 and Day 8 in Part B are the first days of two periods in crossover bioavailability assessment of two AZD6244 formulations: capsule versus the free-base suspension., Days 1 and 8: Pre-dose (within 30 minutes of dosing); 5, 15, and 30 minutes, 1, 1.5, 2, 4, 8, 12, and 24 hours post-dose|Time to Reach Maximum Plasma Concentration (Tmax) of AZD6244 (Part A), The Tmax of AZD6244 in Part A is reported., Day 1: Pre-dose (within 30 minutes of dosing); 5, 15, and 30 minutes, 1, 1.5, 2, 4, 8, 12, and 24 hours post-dose; Day 8: Pre-dose (within 10 minutes of dosing); 5, 15, and 30 minutes, 1, 1.5, 2, 4, 8, and 12 hours post-dose|Tmax of AZD6244 (Part B Single Dose), The Tmax of AZD6244 in Part B is reported. Day 1 and Day 8 in Part B are the first days of two periods in crossover bioavailability assessment of two AZD6244 formulations: capsule versus the free-base suspension., Days 1 and 8: Pre-dose (within 30 minutes of dosing); 5, 15, and 30 minutes, 1, 1.5, 2, 4, 8, 12, and 24 hours post-dose|Half-life (t1/2) of AZD6244 (Part A), The t1/2 of AZD6244 in Part A is reported., Day 1: Pre-dose (within 30 minutes of dosing); 5, 15, and 30 minutes, 1, 1.5, 2, 4, 8, 12, and 24 hours post-dose|t1/2 of AZD6244 (Part B Single Dose), The t1/2 of AZD6244 in Part B is reported. Day 1 and Day 8 in Part B are the first days of two periods in crossover bioavailability assessment of two AZD6244 formulations: capsule versus the free-base suspension., Days 1 and 8: Pre-dose (within 30 minutes of dosing); 5, 15, and 30 minutes, 1, 1.5, 2, 4, 8, 12, and 24 hours post-dose|Total Apparent Drug Clearance (CL/F) of AZD6244 (Part A), The CL/F of AZD6244 in Part A is reported., Day 1: Pre-dose (within 30 minutes of dosing); 5, 15, and 30 minutes, 1, 1.5, 2, 4, 8, 12, and 24 hours post-dose; Day 8: Pre-dose (within 10 minutes of dosing); 5, 15, and 30 minutes, 1, 1.5, 2, 4, 8, and 12 hours post-dose|CL/F of AZD6244 (Part B Single Dose), The CL/F of AZD6244 in Part B is reported. Day 1 and Day 8 in Part B are the first days of two periods in crossover bioavailability assessment of two AZD6244 formulations: capsule versus the free-base suspension., Days 1 and 8: Pre-dose (within 30 minutes of dosing); 5, 15, and 30 minutes, 1, 1.5, 2, 4, 8, 12, and 24 hours post-dose|Volume of Distribution at Steady State (Vss/F) of AZD6244 (Part A), The Vss/F of AZD6244 in Part A is reported., Day 1: Pre-dose (within 30 minutes of dosing); 5, 15, and 30 minutes, 1, 1.5, 2, 4, 8, 12, and 24 hours post-dose|Vss/F of AZD6244 (Part B Single Dose), The Vss/F of AZD6244 in Part B is reported. Day 1 and Day 8 in Part B are the first days of two periods in crossover bioavailability assessment of two AZD6244 formulations: capsule versus the free-base suspension., Days 1 and 8: Pre-dose (within 30 minutes of dosing); 5, 15, and 30 minutes, 1, 1.5, 2, 4, 8, 12, and 24 hours post-dose|Cmax of N-desmethyl AZD6244 (Part A), The Cmax of N-desmethyl AZD6244 in Part A is reported., Day 1: Pre-dose (within 30 minutes of dosing); 5, 15, and 30 minutes, 1, 1.5, 2, 4, 8, 12, and 24 hours post-dose; Day 8: Pre-dose (within 10 minutes of dosing); 5, 15, and 30 minutes, 1, 1.5, 2, 4, 8, and 12 hours post-dose|Cmax of N-desmethyl AZD6244 (Part B Single Dose), The Cmax of N-desmethyl AZD6244 in Part B is reported. Day 1 and Day 8 in Part B are the first days of two periods in crossover bioavailability assessment of two AZD6244 formulations: capsule versus the free-base suspension., Days 1 and 8: Pre-dose (within 30 minutes of dosing); 5, 15, and 30 minutes, 1, 1.5, 2, 4, 8, 12, and 24 hours post-dose|AUC of N-desmethyl AZD6244 (Part A), The AUC of N-desmethyl AZD6244 in Part A is reported., Day 1: Pre-dose (within 30 minutes of dosing); 5, 15, and 30 minutes, 1, 1.5, 2, 4, 8, 12, and 24 hours post-dose|AUC(0-12) of N-desmethyl AZD6244 (Part A), The AUC(0-12) of N-desmethyl AZD6244 in Part A is reported., Day 8: Pre-dose (within 10 minutes of dosing); 5, 15, and 30 minutes, 1, 1.5, 2, 4, 8, and 12 hours post-dose|AUC of N-desmethyl AZD6244 (Part B Single Dose), The AUC of N-desmethyl AZD6244 in Part B is reported. Day 1 and Day 8 in Part B are the first days of two periods in crossover bioavailability assessment of two AZD6244 formulations: capsule versus the free-base suspension., Days 1 and 8: Pre-dose (within 30 minutes of dosing); 5, 15, and 30 minutes, 1, 1.5, 2, 4, 8, 12, and 24 hours post-dose|AUC(0-24) of N-desmethyl AZD6244 (Part B Single Dose), The AUC(0-24) of N-desmethyl AZD6244 in Part B is reported. Day 1 and Day 8 in Part B are the first days of two periods in crossover bioavailability assessment of two AZD6244 formulations: capsule versus the free-base suspension., Days 1 and 8: Pre-dose (within 30 minutes of dosing); 5, 15, and 30 minutes, 1, 1.5, 2, 4, 8, 12, and 24 hours post-dose|Tmax of N-desmethyl AZD6244 (Part A), The Tmax of N-desmethyl AZD6244 in Part A is reported., Day 1: Pre-dose (within 30 minutes of dosing); 5, 15, and 30 minutes, 1, 1.5, 2, 4, 8, 12, and 24 hours post-dose; Day 8: Pre-dose (within 10 minutes of dosing); 5, 15, and 30 minutes, 1, 1.5, 2, 4, 8, and 12 hours post-dose|Tmax of N-desmethyl AZD6244 (Part B Single Dose), The Tmax of N-desmethyl AZD6244 in Part B is reported. Day 1 and Day 8 in Part B are the first days of two periods in crossover bioavailability assessment of two AZD6244 formulations: capsule versus the free-base suspension., Days 1 and 8: Pre-dose (within 30 minutes of dosing); 5, 15, and 30 minutes, 1, 1.5, 2, 4, 8, 12, and 24 hours post-dose|t1/2 of N-desmethyl AZD6244 (Part A), The t1/2 of N-desmethyl AZD6244 in Part A is reported., Day 1: Pre-dose (within 30 minutes of dosing); 5, 15, and 30 minutes, 1, 1.5, 2, 4, 8, 12, and 24 hours post-dose|t1/2 of N-desmethyl AZD6244 (Part B Single Dose), The t1/2 of N-desmethyl AZD6244 in Part B is reported. Day 1 and Day 8 in Part B are the first days of two periods in crossover bioavailability assessment of two AZD6244 formulations: capsule versus the free-base suspension., Days 1 and 8: Pre-dose (within 30 minutes of dosing); 5, 15, and 30 minutes, 1, 1.5, 2, 4, 8, 12, and 24 hours post-dose|Cmax of AZD6244 Amide (Part A), The Cmax of AZD6244 amide in Part A is reported., Day 1: Pre-dose (within 30 minutes of dosing); 5, 15, and 30 minutes, 1, 1.5, 2, 4, 8, 12, and 24 hours post-dose; Day 8: Pre-dose (within 10 minutes of dosing); 5, 15, and 30 minutes, 1, 1.5, 2, 4, 8, and 12 hours post-dose|Cmax of AZD6244 Amide (Part B Single Dose), The Cmax of AZD6244 amide in Part B is reported. Day 1 and Day 8 in Part B are the first days of two periods in crossover bioavailability assessment of two AZD6244 formulations: capsule versus the free-base suspension., Days 1 and 8: Pre-dose (within 30 minutes of dosing); 5, 15, and 30 minutes, 1, 1.5, 2, 4, 8, 12, and 24 hours post-dose|AUC(0-12) of AZD6244 Amide (Part A), The AUC(0-12) of AZD6244 amide in Part A is reported., Day 8: Pre-dose (within 10 minutes of dosing); 5, 15, and 30 minutes, 1, 1.5, 2, 4, 8, and 12 hours post-dose|Area Under the Plasma Concentration-time Curve From Time Zero to 4 Hours Post Dose (AUC[0-4]) of AZD6244 Amide (Part B Single Dose), The AUC(0-4) of AZD6244 amide in Part B is reported. Day 1 and Day 8 in Part B are the first days of two periods in crossover bioavailability assessment of two AZD6244 formulations: capsule versus the free-base suspension., Days 1 and 8: Pre-dose (within 30 minutes of dosing); 5, 15, and 30 minutes, 1, 1.5, 2, 4, 8, 12, and 24 hours post-dose|AUC(0-24) of AZD6244 Amide (Part B Single Dose), The AUC(0-24) of AZD6244 amide in Part B is reported. Day 1 and Day 8 in Part B are the first days of two periods in crossover bioavailability assessment of two AZD6244 formulations: capsule versus the free-base suspension., Days 1 and 8: Pre-dose (within 30 minutes of dosing); 5, 15, and 30 minutes, 1, 1.5, 2, 4, 8, 12, and 24 hours post-dose|Tmax of AZD6244 Amide (Part A), The Tmax of AZD6244 amide in Part A is reported., Day 1: Pre-dose (within 30 minutes of dosing); 5, 15, and 30 minutes, 1, 1.5, 2, 4, 8, 12, and 24 hours post-dose; Day 8: Pre-dose (within 10 minutes of dosing); 5, 15, and 30 minutes, 1, 1.5, 2, 4, 8, and 12 hours post-dose|Tmax of AZD6244 Amide (Part B Single Dose), The Tmax of AZD6244 amide in Part B is reported. Day 1 and Day 8 in Part B are the first days of two periods in crossover bioavailability assessment of two AZD6244 formulations: capsule versus the free-base suspension., Days 1 and 8: Pre-dose (within 30 minutes of dosing); 5, 15, and 30 minutes, 1, 1.5, 2, 4, 8, 12, and 24 hours post-dose|Cmax of AZD6244 (Part B Multiple Doses), The Cmax of AZD6244 in Part B is reported., Days 15 and 22: Pre-dose (within 10 minutes of dosing); 1, 2, and 4 hours post-dose|Tmax of AZD6244 (Part B Multiple Doses), The Tmax of AZD6244 in Part B is reported., Days 15 and 22: Pre-dose (within 10 minutes of dosing); 1, 2, and 4 hours post-dose|AUC(0-4) of AZD6244 (Part B Multiple Doses), The AUC(0-4) of AZD6244 in Part B is reported., Days 15 and 22: Pre-dose (within 10 minutes of dosing); 1, 2, and 4 hours post-dose|Area Under the Plasma Concentration-time Curve From Time Zero to Time of the Last Quantifiable Concentration (AUC[0-t]) of AZD6244 (Part B Multiple Doses), The AUC(0-t) of AZD6244 in Part B is reported., Days 15 and 22: Pre-dose (within 10 minutes of dosing); 1, 2, and 4 hours post-dose|Cmax of N-desmethyl AZD6244 (Part B Multiple Doses), The Cmax of N-desmethyl AZD6244 in Part B is reported., Days 15 and 22: Pre-dose (within 10 minutes of dosing); 1, 2, and 4 hours post-dose|Tmax of N-desmethyl AZD6244 (Part B Multiple Doses), The Tmax of N-desmethyl AZD6244 in Part B is reported., Days 15 and 22: Pre-dose (within 10 minutes of dosing); 1, 2, and 4 hours post-dose|AUC(0-4) of N-desmethyl AZD6244 (Part B Multiple Doses), The AUC(0-4) of N-desmethyl AZD6244 in Part B is reported., Days 15 and 22: Pre-dose (within 10 minutes of dosing); 1, 2, and 4 hours post-dose|AUC(0-t) of N-desmethyl AZD6244 (Part B Multiple Doses), The AUC(0-t) of N-desmethyl AZD6244 in Part B is reported., Days 15 and 22: Pre-dose (within 10 minutes of dosing); 1, 2, and 4 hours post-dose|Cmax of AZD6244 Amide (Part B Multiple Doses), The Cmax of AZD6244 amide in Part B is reported., Days 15 and 22: Pre-dose (within 10 minutes of dosing); 1, 2, and 4 hours post-dose|Tmax of AZD6244 Amide (Part B Multiple Doses), The Tmax of AZD6244 amide in Part B is reported., Days 15 and 22: Pre-dose (within 10 minutes of dosing); 1, 2, and 4 hours post-dose|AUC(0-4) of AZD6244 Amide (Part B Multiple Doses), The AUC(0-4) of AZD6244 amide in Part B is reported., Days 15 and 22: Pre-dose (within 10 minutes of dosing); 1, 2, and 4 hours post-dose|AUC(0-t) of AZD6244 Amide (Part B Multiple Doses), The AUC(0-t) of AZD6244 amide in Part B is reported., Days 15 and 22: Pre-dose (within 10 minutes of dosing); 1, 2, and 4 hours post-dose|Percentage Inhibition of Extracellular Signal-regulated Kinase (ERK) Phosphorylation, Percentage inhibition of ERK phosphorylation is reported., 1, 4, 8, and 24 hours post-dose on Day 1 (Part A and Part B) and Day 8 (Part B)
The primary purpose of the study is to assess the safety, tolerability and pharmacokinetics of a capsule of AZD6244 in participants with advanced solid malignancies.